All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
What are the latest advances in targeted therapies for chronic lymphocytic leukemia?
Featured:
Francesc BoschDuring the EHA2021 Virtual Congress and the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Francesc Bosch, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, What are the latest advances in targeted therapies for chronic lymphocytic leukemia (CLL)?
What are the latest advances in targeted therapies for chronic lymphocytic leukemia?
In this video, Bosch outlines the latest advances in targeted therapies for patients with CLL. He summarizes the results from clinical trials presented during EHA and ASCO in this setting.